# **Special Issue**

# The 20th Anniversary of Pharmaceuticals – Recent Advances in Hybridization and Bioconjugation for Drug Discovery

## Message from the Guest Editors

This Special Issue entitled "Recent advances in hybridization and bioconjugation for drug discovery" aims to cover the advances that are being made in relation to the combination of molecules of any nature to improve their therapeutic properties. Contributions may concern the design and obtaining of novel entities, focusing on the merging of different approaches. Some examples of such approaches could be molecular hybrids based on drugs with different mechanisms of action, multitarget therapies, antibody-drug conjugates, or nanoparticle-based conjugates. Chemical strategies for conjugate coupling as the use of linker modulators or crosslinking agents are also considered, as well as the biological evaluation of the new emerging agents that can demonstrate the connection and synergy between the components of the pharmaceutical entity. Thus, this Special Issue invites all researchers in the pharmaceutical and biological chemical field to publish their outstanding work on hybridization and bioconjugation.

## **Guest Editors**

### Dr. Angela Patricia Hernandez

Department of Pharmaceutical Sciences: Pharmaceutical Chemistry, Faculty of Pharmacy, University of Salamanca, CIETUS, IBSAL, 37007 Salamanca, Spain

## Dr. Mª Ángeles Castro

Department of Pharmaceutical Sciences: Pharmaceutical Chemistry, Faculty of Pharmacy, University of Salamanca, CIETUS, IBSAL, 37007 Salamanca, Spain

## Deadline for manuscript submissions

closed (30 June 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



# mdpi.com/si/174645

Pharmaceuticals
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

#### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)

